In this video, Peter K. Kaiser, MD, founding director of the Digital Eye Optical Coherence Tomography Reading Center at the Cole Eye Institute, discusses treatment options for wet age-related macular ...

Market is one of the leading causes of irreversible vision loss in individuals aged 50 and above. With the global aging population increasing rapidly, the burden of AMD is escalating, pushing the ...

Axpaxli is Ocular's main value driver, targeting a large wet AMD market with a differentiated, sustained-release TKI ...

Receiving the SMC recommendation of LYTENAVA™ (bevacizumab gamma) for patients with wet AMD is a significant milestone for our company and a testament to our commitment to improving patient outcomes,” ...

Comprehensive Age-related Macular Degeneration Market Analysis: Trends and Developments Across All Types According to DelveInsight’s analysis, the market for age-related macular degeneration is ...

ISELIN, N.J., June 10, 2025(Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the Scottish Medi ...

Outlook Therapeutics introduces Lytenava in Germany & UK for the treatment of wet AMD: Iselin, New Jersey Tuesday, June 3, 2025, 16:00 Hrs [IST] Outlook Therapeutics, Inc., a biop ...

The Scottish Medicines Consortium (SMC) has accepted Outlook Therapeutics’ Lytenava to treat wet age-related macular ...